Products Details

Product Description

– HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more[1].

Web ID

– HY-155458

Shipping

– Room temperature

Molecular Formula

– C14H14N2O2S

References

– [1]Filipponi P et al. Continuous Flow Synthesis of the PARP-1/2 Inhibitor HYDAMTIQ: Synthetic Strategy, Optimization, and Green Metrics Evaluation[J]. Organic Process Research & Development, 2023.

CAS Number

– 1201832-32-7

Molecular Weight

– 274.34

SMILES

– O=C1NC2=C(C=C(CN(C)C)S2)C3=C(O)C=CC=C31

Clinical Information

– No Development Reported

Research Area

– Cancer; Inflammation/Immunology

Solubility

– 10 mM in DMSO

Target

– PARP

Pathway

– Cell Cycle/DNA Damage;Epigenetics

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=